N-acetyltransferase 2 (NAT2) and glutathione S-transferase μ (GSTM1) in bladder-cancer patients in a highly industrialized area

International Journal of Occupational and Environmental Health

Volumn 3, Issue 2, 1997, Pages 105-110

  Golka, Klaus ^a   Reckwitz, Thomas ^b   Kempkes, Manuela ^a   Cascorbi, Ingolf ^c   Blaszkewicz, Meinolf ^a   Reich, Susanne E ^a   Roots, Ivar ^c   Soekeland, Juergen ^b   Schulze, Harald ^b   Bolt, Hermann M ^a,d  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^b KLINIKUM DORTMUND   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Aromatic amines; Bladder cancer; Genetic predisposition; Glutathione S transferase ; N acetyltransferase 2; Occupational risk factors; Polycyclic aromatic hydrocarbons

Indexed keywords

EID: 0000540647     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/107735297800407686     Document Type: Article

References (48)

1. Rehn L. Blasengeschwuelste bei Fuchsinarbeitern. Arch Klin Chir. 1895;50:588-600.
2. Hauptverband der gewerblichen Berufsgenossenschaften (ed). Beruflich verursachte Krebserkrankungen. Eine Darstellung der im Zeitraum 1978-1994 anerkannten Fälle. St. Augustin: Hauptverband der gewerblichen Berufsgenossenschaften, 1996.
3. Golka K, Schoeps W, Kierfeld G, Bolt HM. Urothelerkrankungen als Berufskrankheit. Versicherungsmedizin. 1994;46:158-61.
4. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191-308.
5. Myslak ZW, Bolt HM. Berufliche Exposition gegenueber Azofarbstoffen und Harnblasenkarzinom-Risiko. Zbl Arbeitsmed. 1988; 38:310-21.
6. Steineck G, Plato N, Norell SE, Hogstedt C. Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med. 1990;17:371-91.
7. Vineis P. Epidemiology of cancer from exposure to arylamines. Environ Health Perspect. 1994;102(suppl 6):7-10.
8. Wynder EL, Onderdonk J, Mantei N. An epidemiological investigation of cancer of the bladder. Cancer. 1963;16:1388-407.
9. Cordier S, Clavel J, Limasset JC, et al. Occupational risks of bladder cancer in France: a multicentre case-control study. Int J Epi-demiol. 1993;22:403-11.
10. Schifflers E, Jamart J, Renard V. Tobacco and occupation as risk factors in bladder cancer a case-control study in Southern Belgium. Int J Cancer. 1987;39:287-92.
11. Golka K, Bandel T, Urfer W, Bolt HM. Berufliche Risikofaktoren fuer Tumoren der Harnblase und der Prostata. Bremerhaven: Wirtschaftsverlag NW, Verlag fuer Neue Wissenschaften, 1995. Schriftenreihe der Bundesanstalt fuer Arbeitsschutz: Forschung; Fb 714.
12. Golka K, Reich SE. Risk factors for malignat tumours of the urinary bladder and the prostate in the German East Ruhr area. In: Frentzel-Beyme R, Ackermann-Liebrich U, Bertazzi A, et al (eds). Environmental Epidemiology in Europe 1995. Bremen, Germany: Bremen Institute for Prevention Research and Social Medicine (BIPS), 1996:51-62.
13. Golka K, Schlaefke S, Dickhut S, Reich SE, Urfer W, Bolt HM. Anwendung statistischer Methoden zur Identifikation beruflicher Risiken fuer maligne Tumoren der Harnblase und der Prostata. Egelsbach: Verlag Haensel-Hohenhausen, 1996. Deutsche Hochschulschriften 1088.
14. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Molec Genet. 1995;4:231-6.
15. Golka K, Prior V, Blaszkewicz M, et al. Occupational history aspects and genetic N-acetyltransferase (NAT2) polymorphism in urothelial cancer patients in Leverkusen, Germany. Scand J Work Environ Health. 1996;22:332-8.
16. Seidegard J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 1986;7:751-3.
17. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85:1159-64.
18. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis. 1994;15: 813-5.
19. Statistisches Bundesamt (ed). Klassifizierung der Berufe. Systematisches und alphabetisches Verzeichnis der Berufsbenennungen. Stuttgart: Metzler-Poeschel Verlag, 1992.
20. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther. 1983;33:355-9.
21. Roehrkasten R, Raats P, Kreher RP, Blaszkewicz M. Synthesis of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 5-acetylamino-6-amino-3-methyluracil (AAMU) on a preparative scale. Z Naturforsch Teil B. In press.
22. Fink K, Adams WS, Pfleiderer W. A new urinary pyrimidine, 5-acetyl-6-amino-3-methyluracil, its isolation, identification and synthesis. J Biol Chem. 1964; 239:4250-6.
23. Cascorbi I, Drakoulis N, Brockmoeller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
24. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmocogenetics. 1995;5:1-17.
25. Brockmoeller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 1996;56:3915-25.
26. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology: preliminary results in Sweden and Denmark. Environ Health Perspect. 1979;29.79-9.
27. Lower GM Jr, Bryan GT. Etiology and carcinogenesis: natural system approaches to causality and control. In: Javadpour N (ed). Principles and Management of Urologic Cancer. Baltimore, MD: Williams and Wilkins, 1979:29-53.
28. Wolf H, Lower GM Jr, Bryan GT. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol. 1980;14:161-5.
29. Cartwright R, Ahmad RA, Barham-Hall D, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982;2:842-5.
30. Woodhouse KW, Adams PC, Clothier A, Mucklow JC, Rawlins MC. N-Acetylation phenotype in bladder cancer. Hum Toxicol. 1982; 1:443-5.
31. Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet. 1983;20: 330-3.
32. Miller ME, Cosgriff JM. Acetylator phenotype in human bladder cancer. J Urol. 1983;130.65-6.
33. Mommsen S, Barfod NM, Aagard J. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis. 1985;6:199-201.
34. Hanssen HP, Agarwal DP, Goedde HW, et al. Association of the N-acetylation polymorphism and environmental factors with bladder carcinogenesis. Eur Urol. 1985;11:263-6.
35. Ladero JM, Kwok CK, Jara C, et al. Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res. 1985;17:96-9.
36. Hanke J, Krajewska B. Acetylation phenotypes and bladder cancer. J Occup Med. 1990;32.917-8.
37. Roots I, Drakoulis N, Brockmoeller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W (ed). Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992:815-41.
38. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol. 1996; 71:123-6.
39. Brockmoeller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res. 1994;54:4103-11.
40. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Pharmacol. 1984;17:459-64.
41. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-27.
42. Braz Vieira da Silva Pontes Z, Vincent-Viry M, Gueguen R, Galteau MM, Siest G. Acetylation phenotypes and biological variation in a French Caucasian population. Eur J Clin Chem Clin Biochem. 1993;31:59-68.
43. Lewalter J, Miksche L. Empfehlungen zur arbeitsmedizinischen Praevention expositions- und dispositionsbedingter Arbeitsstoff-Beanspruchungen. Verh Dt Ges Arbeitsmed 1991;31:135-9.
44. Meal PF, Cocker J, Wilson HK, Gilmour JM. Search for benzidine and its metabolites in urine of workers weighing benzidine-derived dyes. Br J Ind Med. 1981;38:191-3.
45. Dewan A, Jani JP, Patel JS, Gandhi DH, Vatiya MR. Benzidine and its acetylated metabolites in the urine of workers exposed to direct black 38. Arch Environ Health. 1988;43:269-72.
46. Doll R, Vessey MP, Beasley WR, et al. Mortality of gasworkers - final report of a prospective study. Br J Ind Med. 1972,29.394-406.
47. Manz A, Berger J, Waltsgott H. Zur Frage des Berufskrebses bei Beschaeftigten der Gasindustrie. Bremerhaven: Wirtschaftsverlag NW, Verlag fuer Neue Wissenschaften, 1983. Schriftenreihe der Bundesanstalt fuer Arbeitsschutz: Forschung; Fb 352.
48. Hammond EC, Selikoff IJ, Lawther PL, Seidman H. Inhalation of benzpyrene and cancer in man. Ann NY Acad Sci. 1976; 271:116-24.